

Press Release

05 January 2022 09:07:00 CET

IndiTreat® to be distributed in Poland by Perlan Technologies

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today that an agreement has been signed with Perlan Technologies to bring IndiTreat® tests to Polish patients and professionals.

2cureX and Perlan Technologies have signed an agreement by which Perlan Technologies becomes the distributor of IndiTreat® products in Poland. Under the terms of the collaboration, Perlan Technologies will promote IndiTreat® to Polish oncology professionals, sign supply agreements with hospitals and manage the sample logistics between the hospitals and 2cureX labs in Copenhagen.

With almost 40 million people, Poland is one of the large European markets. The country has more than 25,000 new colorectal cancer cases per year, with higher mortality rates than the European average.

Ambitious expansion strategy continues in 2022

With this agreement, 2cureX continues the ambitious expansion strategy started last year. IndiTreat® tests are currently available in 12 European countries and the company has announced plans to be in 20 countries by the end of 2022.

“This is a strong way to start the year” said **Fernando Andreu, CEO of 2cureX**. “Perlan Technologies has a portfolio of molecular biology products that is very complementary to IndiTreat®. It’s a great fit for us, and we are excited to welcome them to 2cureX. We are looking forward to rolling out IndiTreat® together in Poland”.

“IndiTreat® makes Perlan Technologies Oncology product offering even more complete. That we now also will be able to give patients and their doctors the drug respond information before the treatment decision is taken will for sure be of great value and appreciated” said **Wojciech Duljasz, Sales Manager Diagnostics & Genomics Group of Perlan Technologies**.

One of the large IVD markets in Europe

“I am glad we found the right partner to bring IndiTreat® to Poland”, said **Jesper Floyd Kristiansen, VP Business Development at 2cureX**. “This is a large country with an important Oncology ecosystem. There are more than 1,000 Clinical Oncologists in Poland, many of them with important positions in the international cancer scene”.

The agreement has been signed for an initial term of three years, with automatic renewal for successive terms. Other terms of the agreement have not been disclosed. Sales impact of this agreement is expected to show in 2022.

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer

E-mail: fa@2curex.com

Telephone: +45 2279 5399

www.2curex.com

About Perlan Technologies

PERLAN Technologies Polska Sp. z o.o. started its activity in November 1999 under the name Agilent Technologies Poland Sp. z o.o. as part of the implementation of the strategic plan of division of Hewlett Packard. Since May 2002, the company has been operating under the name PERLAN Technologies Polska Sp. z o.o. and is an authorized distributor of the Life Science and Chemical Analysis products from Agilent Technologies.

PERLAN Technologies provides instruments, accessories and complete solutions enabling customers to identify and conduct research of thousands of substances, determining their composition, structure, physical, chemical and biological properties, cellular, metabolic analysis and DNA and RNA analysis.

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first two IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related *In Vitro Diagnostic* (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se

This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-01-05 09:07 CET.

Attachments

IndiTreat® to be distributed in Poland by Perlan Technologies